Population Pharmacokinetics‐Pharmacodynamics and Exposure‐Response of Ropeginterferon Alfa‐2b in Chinese and Japanese Patients With Polycythemia Vera

Population Pharmacokinetics‐Pharmacodynamics and Exposure‐Response of Ropeginterferon Alfa‐2b in Chinese and Japanese Patients With Polycythemia Vera

ABSTRACT Ropeginterferon alfa‐2b (ropeg) represents a new‐generation interferon‐based therapy approved for polycythaemia vera (PV) treatment. This study aimed to elucidate its population pharmacokinetics‐pharmacodynamics (PopPK‐PD) and exposure‐response (E‐R) relationships. A PopPK model was develop...

Full description

Saved in:
Bibliographic Details
Main Authors: Albert Qin, Kazuya Shimoda, Shanshan Suo, Rongfeng Fu, Keita Kirito, Daoxiang Wu, Jason Liao, Haoqi Chen, Lei Wu, Xia Su, Yucheng Gao, Toshiaki Sato, Yaning Li, Jingjing Zhang, Weihong Shen, Wei Wang, Lei Zhang, Jie Jin, Norio Komatsu
Format: Article
Language:English
Published: Wiley 2025-06-01
Series:Pharmacology Research & Perspectives
Subjects:
complete hematologic response (CHR)
exposure‐response (E‐R)
JAK2V617F allele burden
polycythemia vera (PV)
population pharmacokinetics‐pharmacodynamics (PopPK‐PD)
Ropeginterferon alfa‐2b (ropeg)
Online Access:https://doi.org/10.1002/prp2.70109
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/prp2.70109

Similar Items